6/28/23, 11:16 PM MAGPIE Pathway Feedback Search Clinical Topics Home Studies MAGPIE MAGPIE Disease Disease Eclampsia Preeclampsia Trial question What is the role of magnesium sulfate in women with pre-eclampsia, and their babies? Study design Multi-center Double blinded RCT Population 10141 female patients Inclusion criteria: women who had not given birth or were 24 h postpartum with BP 140/90 mmHg and proteinuria 1+ Key exclusion criteria: hypersensitivity to magnesium, hepatic coma with a risk of renal failure, or myasthenia gravis Interventions N=5071 magnesium sulfate (5 g IV) N=5070 placebo (10 mL normal saline) Primary outcome Eclampsia 1.9 % 1.9 1.4 % 0.9 % 0.8 0.5 % https://web.pathway.md/studies/recfYK1lBXhuodRBD 1/2 6/28/23, 11:16 PM MAGPIE Pathway Borderline significant decrease 0.0 % Magnesium sulfate Placebo Borderline significant decrease in eclampsia (0.8% vs. 1.9%; RR 0.42, 95% CI 0.29 to 0.6) Secondary outcomes No significant difference in maternal death (0.2% vs. 0.4%; RR 0.55, 95% CI 0.26 to 1.14) No significant difference in neonatal death (12.7% vs. 12.4%; RR 1.02, 99% CI 0.92 to 1.14) Safety outcomes Significant difference in side effects (24% vs. 5%). Conclusion In women who had not given birth or were 24 h postpartum with BP 140/90 mmHg and proteinuria 1+, magnesium sulfate was superior to placebo with respect to eclampsia. Reference Altman D, Carroli G, Duley L et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1;359(9321):1877-90. Open reference URL https://web.pathway.md/studies/recfYK1lBXhuodRBD 2/2